Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Leading Medical Cannabis Advocate United Patients Group Calls for New Research into Cancer-Killing Effects of Cannabis Extracts
  • USA - English


News provided by

United Patients Group

Feb 07, 2014, 03:05 ET

Share this article

Share toX

Share this article

Share toX

United Patients Group - Your Resource For Alternative Medicine
United Patients Group - Your Resource For Alternative Medicine

San Francisco, CA (PRWEB) February 07, 2014 -- United Patients Group today announced a call for research into the therapeutic effects of cannabis extracts in cancer, given the growing and clear evidence indicating cannabis has anticancer effects in humans. They are urging known philanthropists and individuals interested in cancer breakthroughs to help fund clinical trials of the cancer-destroying power of cannabis extracts.

This overwhelming evidence of the power of cannabis to treat cancer has lead doctors to call for further research

Post this

“A number of recent studies have shown that medical cannabis does much more than improve patient’s symptoms—it may, in fact, be a substantial anticancer treatment itself,” said John Malanca, founder and owner of United Patients Group, a trusted news source and advocate for medical cannabis patients. “Yet the federal government ignores these studies and refuses to fund research in this area (even though they hold a patent on cannabis as a therapeutic treatment - US Patent #6630507.

Because of this, we’re calling on individuals who are dedicated to saving lives to jump-start more research into these medicinal compounds that hold tremendous potential.

“Philanthropic individuals, we are in need of your help in fast-tracking this research. The government refuses to see what’s already evident: that cannabis extracts can kill cancer cells. So we’re asking people like Sir Richard Branson, Sara Blakely, John Paul DeJoria, Ted Turner, George Lucas, Bill Gates, Michael Ashcroft, Dan and Jennifer Gilbert, and other powerful advocates of human health to fund rigorous scientific research into these compounds that could potentially save millions of lives,” he urged.

A recent blog post, entitled, "Cannabis Extract Treatment for Terminal Acute Lymphoblastic Leukemia" on UnitedPatientsGroup.com collects some of the groundbreaking studies that have demonstrated that certain cannabis compounds damage and kill cancer cells. These studies include the following:

• A 2013 article in Case Reports in Oncology profiled the case of a 14-year-old girl with lymphoblastic leukemia. Traditional treatments had failed to help her, so she began taking cannabis oil. Her leukemic blast cell count plunged from 374,000 to 300 in just over a month. Unfortunately, the patient passed away from side effects from prior chemotherapy and radiation treatments.

• A 2011 study published in Child’s Nervous System, the official journal of the International Society for Pediatric Neurosurgery, found an association between cannabis inhalation and brain-tumor regression in two adolescent patients. The patients both had residual tumors from pilocytic astrocytoma, and inhaling cannabis regularly resulted in a “clear regression” of their tumors over the course of three years, with no other treatment concurrent.

• Many animal studies have shown that the cannabinoid THC, a primary medicinal compound in cannabis, inhibits and induces cell death in cancers including brain cancer, prostate cancer, colorectal cancer, pancreatic cancer, and leukemia.

• Another cannabinoid, CBD, has also been shown in animal studies to kill multiple kinds of cancer cells, and studies suggest that multiple cannabinoids act together to create a synergistic cancer-killing effect.

Anecdotal evidence of the incredible healing powers of cannabis is compelling. Dr. Stanley Rutner went from ten days to live to "No Evidence of Cancer" when he began taking cannabis oil in a daily regimen.

Cash Hyde, a four-year-old with brain cancer, was brought back from the brink of death several times by cannabis oil, but he ultimately succumbed when his family was unable to obtain enough oil to keep his treatment going.

Hundreds of additional cases have demonstrated similar results.

This overwhelming evidence of the power of cannabis to treat cancer has lead doctors to call for further research. Dr. Yadenver Singh and Dr. Mansoor Foroughi, authors of the referenced studies in Case Reports in Oncology and Child’s Nervous System, respectively, and the latter a recipient of the 2013 Braakman award from the European Association of Neurological Surgeons, each concluded that clinical trials should be undertaken.

Dr. Raphael Mechoulam, the iconic Israeli researcher who discovered tetrahydrocannabinol (THC) in 1964, and whose lab discovered the first endocannabinoid anandamide in 1992, strongly suggests that such trials “should be planned and undertaken as soon as possible.”

Dr. Sunil Aggarwal, a 2014–15 Clinical Fellow in Hospice and Palliative Medicine at the National Institutes of Health Clinical Center, joins this call for research.

“For the good of the human race, we ask these powerful individuals, who have shown their dedication to easing human suffering, to step up and help fund these clinical trials and for government to facilitate this important research,” implored Malanca.

For more information about this topic, visit UnitedPatientsGroup.com or call (415) 524-8099.

About UnitedPatientsGroup.com
UnitedPatientsGroup.com is a discreet, safe, and professional online medical cannabis information resource for prospective and current patients, caregivers, and medicinal cannabis industry professionals.

While most online medical marijuana sites cater to patients already familiar with medical marijuana, the UnitedPatientsGroup.com website is a comprehensive and easy-to-use information source for people of all ages and experience levels, from novice medical cannabis users to experienced industry professionals. The site’s News, Resource, and Blog pages introduce new patients to the ins and outs of medical marijuana healthcare, while helping experienced providers stay abreast of the latest developments in THC and CBD therapies.

A complimentary Five Star-rated United Patients Group medical marijuana app is available on the iTunes app store for iPhone 3GS, iPhone 4, iPhone 4S, iPhone 5, iPod touch (3rd generation), iPod touch (4th generation) and any iPad.

John Malanca, United Patients Group, http://www.unitedpatientsgroup.com/, +1 (415) 524-8099, [email protected]

Modal title

United Patients Group - Your Resource For Alternative Medicine
United Patients Group - Your Resource For Alternative Medicine
United Patients Group - Your Resource For Alternative Medicine

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.